Higher expression of whole blood microRNA-21 in patients with ankylosing spondylitis associated with programmed cell death 4 mRNA expression and collagen cross-linked C-telopeptide concentration

Journal of Rheumatology

Volumn 41, Issue 6, 2014, Pages 1104-1111

  Huang, Chun Huang ^a   Wei, James Cheng Chung ^a   Chang, Wei Chiao ^c   Chiou, Shang Yan ^b   Chou, Chia Hsuan ^b   Lin, Yu Jie ^b   Hung, Pei Hsuan ^b   Wong, Ruey Hong ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Ankylosing spondylitis; Collagen cross linked C telopeptide; MicroRNA 21; Programmed cell death 4

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; MESSENGER RNA; MICRORNA 21; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; APOPTOSIS REGULATORY PROTEIN; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; MICRORNA; MIRN21 MICRORNA, HUMAN; PDCD4 PROTEIN, HUMAN; PEPTIDE; RNA BINDING PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD ANALYSIS; BONE EROSION; CONTROLLED STUDY; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGRAMMED CELL DEATH 4 GENE; REAL TIME POLYMERASE CHAIN REACTION; ADOLESCENT; AGED; BLOOD; GENETICS; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; APOPTOSIS REGULATORY PROTEINS; COLLAGEN TYPE I; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PEPTIDES; RNA, MESSENGER; RNA-BINDING PROTEINS; SPONDYLITIS, ANKYLOSING; YOUNG ADULT;

EID: 84901725791     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130515     Document Type: Article

References (38)

1. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379-90. (Pubitemid 46590387)
2. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL-A 27. Lancet 1973;1:904-7.
3. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci 2006;1092:385-96. (Pubitemid 47092355)
4. Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. J Rheumatol 2005;32:1290-8. (Pubitemid 40995385)
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
6. Tili E, Michaille JJ, Croce CM. MicroRNAs play a central role in molecular dysfunctions linking inflammation with cancer. Immunol Rev 2013;253:167-84.
7. Fujita S, Ito T, Mizutani T, Minoguchi S, Yamamichi N, Sakurai K, et al. miR-21 Gene expression triggered by AP-1 is sustained through a double-negative feedback mechanism. J Mol Biol 2008;378:492-504.
8. Asahara H, Fujisawa K, Kobata T, Hasunuma T, Maeda T, Asanuma M, et al. Direct evidence of high DNA binding activity of transcription factor AP-1 in rheumatoid arthritis synovium. Arthritis Rheum 1997;40:912-8. (Pubitemid 27200009)
9. Sugatani T, Vacher J, Hruska KA. A microRNA expression signature of osteoclastogenesis. Blood 2011;117:3648-57.
10. Loh PG, Yang HS, Walsh MA, Wang Q, Wang X, Cheng Z, et al. Structural basis for translational inhibition by the tumour suppressor Pdcd4. EMBO J 2009;28:274-85.
11. Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
12. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem 2011;57:84-91.
13. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 2012;5:492-7.
14. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 2011;57:833-40.
15. Rosen HN, Moses AC, Garber J, Iloputaife ID, Ross DS, Lee SL, et al. Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcif Tissue Int 2000;66:100-3. (Pubitemid 30056702)
16. Muntean L, Rojas-Vargas M, Font P, Simon SP, Rednic S, Schiotis R, et al. Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. Clin Rheumatol 2011;30:691-5.
17. Zhang Z, DuBois RN. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 2011;20:4450-6.
18. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
19. Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, Jan MS, et al. Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 2007;26:1685-91.
20. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9. (Pubitemid 40075289)
21. Chou CT, Tsai YF, Liu J, Wei JC, Liao TS, Chen ML, et al. The detection of the HLA-B27 antigen by immunomagnetic separation and enzyme-linked immunosorbent assay-comparison with a flow cytometric procedure. J Immunol Methods 2001;255:15-22. (Pubitemid 32695379)
22. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8. (Pubitemid 351818697)
23. Mermerci Başkan B, Pekin Doǧan Y, Sivas F, Bodur H, Ozoran K. The relation between osteoporosis and vitamin D levels and disease activity in ankylosing spondylitis. Rheumatol Int 2010;30:375-81.
24. Cohen JD, Cunin P, Farrenq V, Oniankitan O, Carton L, Chevalier X, et al. Estimation of the Bath Ankylosing Spondylitis Disease Activity Index cutoff for perceived symptom relief in patients with spondyloarthropathies. J Rheumatol 2006;33:79-81. (Pubitemid 43054284)
25. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003;62:817-24. (Pubitemid 37026490)
26. Sugatani T, Hruska KA. Down-regulation of miR-21 biogenesis by estrogen action contributes to osteoclastic apoptosis. J Cell Biochem 2013;114:1217-22.
27. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27:4373-9. (Pubitemid 352010003)
28. Amor B, Dougados M, Listrat V, Menkes CJ, Roux H, Benhamou C, et al. Are classification criteria for spondylarthropathy useful as diagnostic criteria? Rev Rhum Engl Ed 1995;62:10-5.
29. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 2006;33:722-31.
30. Yasuda M, Schmid T, Rübsamen D, Colburn NH, Irie K, Murakami A. Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 2010;49:837-48.
31. Smith MD, Weedon H, Papangelis V, Walker J, Roberts-Thomson PJ, Ahern MJ. Apoptosis in the rheumatoid arthritis synovial membrane: modulation by disease-modifying anti-rheumatic drug treatment. Rheumatology 2010;49:862-75.
32. Maillefert JF, Aho LS, El Maghraoui A, Dougados M, Roux C. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. Osteoporos Int 2001;12:605-9. (Pubitemid 32777439)
33. Kapinas K, Delany AM. MicroRNA biogenesis and regulation of bone remodeling. Arthritis Res Ther 2011;13:220.
34. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res 2008;79:581-8.
35. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol 2009;182:4994-5002.
36. Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010;69:1065-71.
37. Hamilton AJ. MicroRNA in erythrocytes. Biochem Soc Trans 2010;38:229-31.
38. Tam LS, Gu J, Yu D. Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol 2010;6:399-405.